Episode 62
Biotech Hangout
00:00
CT DNA: A Biomarker of Therapeutic Effect
The MUNICORES Kim Track had, um, basically in a phase three UVL melanoma trial, a profound survival benefit on essentially against PD1 antibodies. Autolus has some data for Obercell, which is a CAR-T product that they're developing for an A-L-L B cell. They have what looks like a much lower rate of cytokine release syndrome and neurotox than Gilead's decardis. And so I think CT DNA is actually making a lot of progress as a very good, um, biomarker of therapeutic effect.
Transcript
Play full episode
